MarketVIEW Hospital & AMR Vaccines  ·  September 2018 edition

E.coli (ExPEC)
Vaccines Forecast

Extraintestinal pathogenic E.coli overtook Staphylococcus as the leading cause of bloodstream infection back in 2009, yet no vaccine has ever been licensed against it. The field's most advanced trial to date, Janssen and Sanofi's Phase 3 ExPEC9V programme, fell short in February 2025, leaving GSK's earlier-stage candidate as the best remaining hope. This is the independent commercial assessment of what a workable vaccine could still be worth, drawing on VacZine Analytics' long-standing, independent authority in Hospital and AMR vaccine markets.

Phase 3 ExPEC9V Discontinued (Feb 2025) Leading Cause of Bacteraemia Since 2009 Major Western Markets to 2035 CDC Urgent AMR Threat
Product catalogue
VAMV064
September 2018 edition

Format
Executive presentation + Excel model
Coverage
Major Western markets
Vaccines assessed
ExPEC9V, ExPEC10V, GSK UPEC
Forecast horizon
To 2035
Approach
LO / BASE / HI scenarios
Base edition
September 2018
Availability
Syndicated / bespoke
96,560
US E. coli bacteraemias in 2013,
up 109% from 46,140 in 2000
12%
Of women reporting a UTI
in the past 12 months (NHANES III)
~20,000
Participants in ExPEC9V's
discontinued Phase 3 E.mbrace 3 trial
$250M
Impairment charge taken by Sanofi
after the 2025 trial discontinuation
Disease background

Why ExPEC has remained a stubborn vaccine target

Extraintestinal pathogenic E.coli is among the most consequential bacterial pathogens in modern healthcare, and, until very recently, one of the field's most promising vaccine opportunities. Understanding both the scale of the clinical burden and why the field's most advanced candidate has just failed is central to understanding what a workable vaccine could still be worth.

CDC EIP 2023 data & 2025 pipeline

Pathogen overview - Extraintestinal pathogenic E.coli (ExPEC)

Extraintestinal pathogenic E.coli (ExPEC) is a member of the Enterobacteriaceae bacterial family and a leading cause of healthcare-associated infections, including bacteraemia, urinary tract infections (UTIs), neonatal sepsis and meningitis. Based on principal-diagnosis US hospital discharge data, E. coli bacteraemias rose to 96,560 in 2013, up from 46,140 in 2000, an increase of 109%. Streptococcal, staphylococcal and pneumococcal bacteraemias also increased over the same period, but E. coli overtook Staphylococcus as the leading cause of bacteraemia in 2009, and carbapenem-resistant E. coli is considered an urgent threat by the US CDC.

E.coli is also the most frequent cause of community-acquired, uncomplicated UTIs, a common driver of US emergency department and primary care visits; according to NHANES III, around 12% of women reported a UTI in the past 12 months. CDC's Emerging Infections Program has since sharpened this picture: active surveillance across nine US communities in 2023 found a higher incidence of invasive ExPEC infection than previously recognised, while urinary surveillance at three sites found that 22.5% of UTI patients experienced recurrence and 3.6% went on to develop E. coli bacteraemia. Antimicrobial resistance continues to climb, with 7.8% of surveyed urinary isolates extended-spectrum beta-lactamase producing, a trend linked to an ageing population and rising comorbidities.

No vaccine has ever been licensed against ExPEC. Janssen's multivalent O-antigen bioconjugate programme progressed furthest: an earlier 10-valent formulation, ExPEC10V, completed Phase 1/2a testing in adults aged 60 and over with a history of UTI, before the programme advanced to a 9-valent formulation, ExPEC9V, partnered with Sanofi. In February 2025, an independent data monitoring committee halted ExPEC9V's pivotal Phase 3 trial (E.mbrace 3), which had enrolled almost 20,000 participants aged 60 and over across 250 sites on five continents, after determining the vaccine was not sufficiently effective at preventing invasive E. coli disease compared with placebo. No safety concerns were identified, but Sanofi recorded a 250 million US dollar impairment charge as a result.

That failure leaves the field's development activity concentrated in earlier-stage candidates. GSK maintains an undisclosed-stage uropathogenic E. coli (UPEC) vaccine within its published pipeline as of its 2025 and 2026 clinical trials reports, positioning it as the most visible remaining hope following the ExPEC9V setback.

2026 96,560 US bacteraemias (2013), +109% vs 2000  |  leading cause of bacteraemia since 2009  |  ExPEC9V Phase 3 discontinued Feb 2025  |  GSK's UPEC candidate now the most visible hope
Product & competitor landscape

The field's most advanced trial yet fell short in 2025

ExPEC9V represented nearly two decades of bioconjugate vaccine development and the largest clinical trial ever run against this pathogen. Its failure in February 2025 is the field's most significant setback to date, and it resets expectations for every candidate that follows.

  • Janssen / SanofiPhase 3, discontinued 2025
    ExPEC9V 9-valent O-antigen bioconjugate
    The field's most advanced candidate, targeting invasive ExPEC disease prevention in adults 60 and over with a history of UTI. The pivotal Phase 3 E.mbrace 3 trial, enrolling almost 20,000 participants across 250 sites on five continents, was discontinued in February 2025 after failing to show sufficient efficacy versus placebo. No safety concerns were identified; Sanofi recorded a 250 million US dollar impairment charge.
  • JanssenPhase 1/2a complete
    ExPEC10V (VAC52416) 10-valent bioconjugate
    An earlier 10-valent formulation of Janssen's O-antigen bioconjugate platform, tested in a Phase 1/2a trial in adults aged 60 and over with a history of UTI, ahead of the programme's advancement to the 9-valent ExPEC9V formulation.
  • GSKPipeline, stage undisclosed
    UPEC vaccine candidate
    A uropathogenic E. coli vaccine candidate listed in GSK's published pipeline as of its 2025 and 2026 clinical trials reports, with development stage not yet disclosed in detail. Now the field's most visible remaining hope following ExPEC9V's discontinuation.
  • Academic & subunit approachesLargely dormant
    Whole-cell and subunit candidates
    Earlier subunit and whole-cell vaccine approaches were investigated historically but have not advanced into active clinical development, leaving bioconjugate technology as the field's dominant platform.
Market reset
2025

ExPEC9V's discontinuation is the ExPEC vaccine field's most significant setback to date, following almost two decades of bioconjugate vaccine development and the largest clinical trial ever run against this pathogen. It leaves GSK's earlier-stage UPEC candidate as the field's best remaining hope, and raises fundamental questions about target antigen selection and population targeting that any successor programme will need to answer. The underlying opportunity has not gone away: ExPEC remains the leading cause of bacteraemia in Western healthcare systems. The VacZine Analytics model quantifies the commercial opportunity under multiple pipeline-recovery scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW ExPEC analysis combines detailed indication-level modelling with the post-2025 competitor landscape and scenario-based revenue forecasting across major Western markets to 2035.

Patient forecast across Western markets

Bottom-up modelling of a putative ExPEC vaccine across major Western markets to 2035, with value ($m) and volume (million doses) outputs.

Competitor & pipeline review

ExPEC9V's 2025 Phase 3 failure, ExPEC10V's earlier Phase 1/2a data, and GSK's earlier-stage UPEC candidate.

Indication & TPP assessment

Commercial and clinical feasibility of preventing invasive ExPEC disease in at-risk and non-risk adults versus preventing recurrent UTIs in women aged 18 to 64.

Scenario-based revenue forecasts

LO, BASE and HI scenarios reflecting different levels of population targeting, launch timeframe, pricing and penetration assumptions.

Disease burden & epidemiology

Updated US bacteraemia and UTI burden drawing on CDC's Emerging Infections Program 2023 surveillance, and rising antimicrobial resistance trends.

Post-failure market reset & path forward

Lessons from ExPEC9V's Phase 3 miss, implications for antigen selection and population targeting, and the outlook for the pipeline behind it.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full value/volume outputs, pricing assumptions and market-level data are in the licensed model.

Target populationGeographyIndicationVaccine profileRevenue scenario
Adults 18+ (risk and non-risk)Major Western marketsInvasive ExPEC disease preventionBioconjugateModelled
Women 18-64 with recurrent UTI historyMajor Western marketsRecurrent UTI preventionBioconjugateModelled
High AMR-risk elderly cohortMajor Western marketsInvasive ExPEC disease preventionBioconjugateModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseMajor Western marketsAll indicationsAll profiles$███m
Full model in the licensed workbook
To 2035 · LO/BASE/HI · indication split · pricing detail
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the ExPEC vaccine opportunity.

  • Executive presentation - disease background, epidemiology, the ExPEC9V Phase 3 failure, competitor pipeline and full commercial assessment with supporting narrative and references
  • MS-Excel forecast model - value ($m) and volume (million doses) predictions to 2035 across major Western markets, with launch timeframe, TPP, pricing and penetration estimates
  • LO / BASE / HI scenario forecasts - based on the level of population targeted by a potential vaccine, reflecting the post-2025 pipeline reset
  • Competitor intelligence - Janssen/Sanofi's ExPEC9V and ExPEC10V, and GSK's earlier-stage UPEC candidate
  • Updated epidemiology module - CDC EIP 2023 bacteraemia and UTI surveillance data, and rising antimicrobial resistance trends
  • Indication & TPP assessment - invasive ExPEC disease prevention versus recurrent UTI prevention, target population rationale and pricing feasibility
Target audience

Built for organisations weighing the ExPEC opportunity

Most valuable to teams evaluating the ExPEC vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of ExPEC9V's 2025 Phase 3 failure and what it means for the candidates left standing.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for ExPEC candidates at any stage.

Corporate strategy & BD

Validate the market size and structure after ExPEC9V's failure, and understand what it means for earlier-stage competitors.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on ExPEC and adjacent Hospital/AMR vaccine assets.

Hospital & infection control programmes

Demand modelling and prevention-strategy context for hospital epidemiology and infection control teams.

Researchers & academia

Comprehensive epidemiology and vaccine landscape for grant and translational planning, including the ExPEC9V trial findings.

Market access & policy

Pricing benchmarks and access-pathway assumptions across public and private Hospital/AMR channels.

About this analysis · VAMV064

VacZine Analytics has tracked Hospital and AMR vaccine markets since our earliest editions, positioning us to reassess the ExPEC opportunity the moment the pipeline changed. This analysis combines a rigorous epidemiological and clinical review with an independently constructed commercial model spanning major Western markets that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis, which has been well received by clients across the field.

This September 2018 edition has been updated to incorporate the full detail of ExPEC9V's February 2025 Phase 3 discontinuation and GSK's emerging UPEC candidate. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV064 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc ExPEC analysis, a briefing call is included on request.